AsiaOne examines how groups are working to prepare policy makers for the availability of a dengue vaccine in the future, following a three-day meeting on the virus held in Singapore this week (Chan, 12/3).
‘Complacency Is Dangerous’ In Global HIV/AIDS Fight: A Lancet Editorial is critical of UNAIDS Executive Director Michel Sidibe’s statement in the annual UNAIDS reportÂ that “We have halted and begun to reverse the epidemic.” The editorial states, “These words, from the head of a U.N. agency, are reckless and premature, and…
Former Norwegian Health Minister To Chair GAVI Alliance Board The GAVI Alliance Board announced on Tuesday that it “has elected former Norwegian Health Minister and current MP Dagfinn Hoybraten as its new chairman, succeeding Mary Robinson,” PANA/Afrique en ligne reports (11/30).Â Hoybraten “has been a member of the GAVI Board since…
GAVI Says Pentavalent Vaccine Price To Fall, But $3.7B Still Needed To Vaccinate Children In Developing Countries
The average price of a vaccine that protects children against five diseases is expected to “drop to $2.58 next year compared to the current average price of $2.97,” the GAVI Alliance said Friday, Reuters reports. The group credits the expected price decline, which “represents a decrease of 30 percent over the last seven years,” in part to an “increased demand for the pentavalent, or five-in-one vaccine,” according to the news service (Kelland, 11/26).
Haiti needs about 1,000 additional trained nurses and at least 100 more physicians to control the cholera epidemic, Valerie Amos, the U.N. undersecretary-general for humanitarian affairs, said during a recent visit to the capital of Port-au-Prince, Reuters reports. “We clearly need to do more,” Amos said of the global response to the cholera outbreak. “But it’s not just money, it’s crucially people, in terms of getting more doctors, nurses, more people who can help with the awareness-raising and getting information out there,” she said. The U.N. plans to work with countries and aid groups that have the capacity to quickly provide more health workers, according to Amos.
At a press conference in London, health officials said that the anticipated roll-out of the MenAfriVac for meningitis in three African countries will start on Dec. 6, the BBC reports. “The vaccine, which has been developed in India, costs less than fifty U.S. cents a dose and clinical tests suggest it could offer protection for between 10 and 15 years,” the news service writes (Bowdler, 11/22).
Study Estimates Cost Savings Associated With Global Polio Eradication; Global Post Examines Vaccination Efforts In Africa
Research published in the November issue of the journal Vaccine found that a global campaign to eliminate polio could save between $40 billion and $50 billion “over the next few decades if the crippling disease is wiped out within five years,” Bloomberg reports (Gale, 11/22).
Also In Global Health News: Reports Of Misuse Of Global Fund Grants; 2007-2008 Food Crisis; Polio Vaccination Drive In Uganda
Southern Times Examines Reports Of Misuse Of Global Fund Grants In Zambia The Southern Times reports that Zambia has been named one of four African countries identified by the Global Fund’s Office of the Inspector General to have misused a combined amount of $25 million in grants. As was first…
Also In Global Health News: Bird Flu In Hong Kong; Counterfeit Drugs In Africa; Dep. Sec. Of State For Management, Resources; HIV/AIDS In S. Africa; World Toilet Day
Bird Flu Case In Hong Kong Isolated Health officials in Hong Kong confirmed on MondayÂ that the woman diagnosed with H5N1 (bird) flu after a trip to China this monthÂ is now in stable conditionÂ and did not contract a new strain of the virus, SAPA/DPA/Mail & Guardian report. Additionally, her case appears…
Also In Global Health News: Nigerian Drug Institute Funding; Food Security, Climate Change; Heat-Stable, Nasal Vaccine Works In Mice; Task-Shifting In Swaziland; Bird Flu In Hong Kong
Nigerian Drug Research Institute Halts Research Because Of Funding Shortfall Nigeria’s National Institute for Pharmaceutical Research and Development (NIPRD), which focuses on developing traditional herbal remedies into drug candidates,Â has had to discontinue research after the Nigerian health ministry did not provide the full amount of expected fundingÂ and a “key grant…